title: CCAR2 deficiency augments genotoxic stress-induced apoptosis in the presence of melatonin in non-small cell lung cancer cells.
abstract: Melatonin exhibits oncostatic activity in several cancers but does not lead to cytotoxicity in estrogen receptor (ER)-negative non-small cell lung cancers (NSCLCs). In an effort to overcome the melatonin resistance of these cancers, we investigated whether cell cycle and apoptosis regulator 2 (CCAR2) depletion would promote apoptosis following genotoxic stress in melatonin-resistant cancer cells. Ordinarily, the NSCLC cell lines A549 and A427 did not undergo cell death following melatonin treatment for short period. These cell lines were irradiated with UV, a source of genotoxic damage, to trigger apoptotic signaling. Treatment with melatonin prior to irradiation did not produce any significant change in apoptosis. By contrast, in CCAR2-deficient cells, melatonin treatment increased apoptosis induced by genotoxic stress; this effect was dependent on the dose of melatonin. The increase in apoptosis in CCAR2-deficient cells was not dependent on SIRT1. The results indicate that CCAR2 is critical for maintaining cell survival in the presence of melatonin under genotoxic stress. Furthermore, CCAR2 is overexpressed in NSCLC; therefore, melatonin could be used as a potential supplement to classical anticancer drugs in therapies against CCAR2-deficient cancers.
authors.affiliation: Department of Pharmacology, School of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 130-701, Republic of Korea.
authors.forename: Wootae
authors.initials: W
authors.lastname: Kim
authors.forename: Joo-Won
authors.initials: JW
authors.lastname: Jeong
authors.forename: Ja-Eun
authors.initials: JE
authors.lastname: Kim
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000172:deficiency* / Q000235:genetics; D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D000975:Antioxidants / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D015153:Blotting, Western; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D049109:Cell Proliferation; D004249:DNA Damage / Q000187:drug effects* / Q000528:radiation effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008550:Melatonin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014466:Ultraviolet Rays
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000975:Antioxidants; C527450:CCAR2 protein, human; D008550:Melatonin
references.citation: J Biol Chem. 2009 Mar 20;284(12):7542-52
references.pmid: 19131338
references.citation: J Mol Cell Biol. 2012 Oct;4(5):294-303
references.pmid: 22735644
references.citation: Pathology. 2013 Oct;45(6):574-80
references.pmid: 24018803
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4417-26
references.pmid: 18579664
references.citation: PLoS One. 2013 Sep 03;8(9):e74738
references.pmid: 24019980
references.citation: Cancer Res. 1988 Nov 1;48(21):6121-6
references.pmid: 3167858
references.citation: Br J Cancer. 2010 Mar 16;102(6):1061-7
references.pmid: 20160719
references.citation: Neoplasma. 2010;57(4):365-8
references.pmid: 20429629
references.citation: Endocr Relat Cancer. 2003 Jun;10(2):153-9
references.pmid: 12790777
references.citation: Adv Med Sci. 2007;52:11-28
references.pmid: 18217386
references.citation: Cancer Sci. 2010 Jul;101(7):1738-44
references.pmid: 20412117
references.citation: In Vivo. 2007 May-Jun;21(3):513-8
references.pmid: 17591362
references.citation: Lung Cancer. 2002 Aug;37(2):153-9
references.pmid: 12140138
references.citation: Nature. 2008 Jan 31;451(7178):583-6
references.pmid: 18235501
references.citation: J Biol Chem. 2010 Dec 24;285(52):40830-7
references.pmid: 21030595
references.citation: J Biol Chem. 2009 Mar 13;284(11):6832-40
references.pmid: 19126541
references.citation: Mol Cell Endocrinol. 2002 Jun 28;192(1-2):147-56
references.pmid: 12088876
references.citation: J Pineal Res. 2011 Mar;50(2):140-9
references.pmid: 21062352
references.citation: Expert Opin Ther Targets. 2013 Dec;17(12):1483-96
references.pmid: 24032643
references.citation: Nature. 2012 Mar 25;484(7394):386-9
references.pmid: 22446626
references.citation: J Pineal Res. 2009 Aug;47(1):8-14
references.pmid: 19522739
references.citation: Biochem Pharmacol. 1994 Jan 20;47(2):197-202
references.pmid: 8304964
references.citation: Korean J Physiol Pharmacol. 2010 Dec;14(6):365-9
references.pmid: 21311676
references.citation: In Vivo. 2009 Sep-Oct;23(5):739-45
references.pmid: 19779109
references.citation: Clin Cancer Res. 2009 Jul 1;15(13):4453-9
references.pmid: 19509139
references.citation: Oncol Rep. 1995 Sep;2(5):871-3
references.pmid: 21597833
references.citation: Int J Clin Oncol. 2014 Feb;19(1):106-12
references.pmid: 23299276
references.citation: J Pineal Res. 2001 May;30(4):243-7
references.pmid: 11339514
references.citation: Mol Endocrinol. 2007 Jul;21(7):1526-36
references.pmid: 17473282
references.citation: Biochem J. 2013 May 1;451(3):453-61
references.pmid: 23398316
references.citation: J Pineal Res. 2005 Aug;39(1):12-20
references.pmid: 15978052
references.citation: J Pineal Res. 2013 Sep;55(2):184-94
references.pmid: 23711089
references.citation: J Pineal Res. 2003 Jan;34(1):1-10
references.pmid: 12485365
references.citation: Int J Alzheimers Dis. 2011;2011:326320
references.pmid: 21629741
references.citation: Trends Pharmacol Sci. 2005 Aug;26(8):412-9
references.pmid: 15992934
references.citation: Prostate. 2005 Apr 1;63(1):29-43
references.pmid: 15378522
references.citation: J Pharm Pharmacol. 2002 Oct;54(10):1299-321
references.pmid: 12396291
references.citation: J Pineal Res. 2008 May;44(4):397-407
references.pmid: 18086147
references.citation: Integr Cancer Ther. 2009 Dec;8(4):337-46
references.pmid: 20050373
references.citation: Korean J Pathol. 2012 Dec;46(6):523-31
references.pmid: 23323102
references.citation: Biochem Biophys Res Commun. 2010 Feb 12;392(3):357-62
references.pmid: 20074560
references.citation: Transl Oncol. 2013 Jun 01;6(3):370-81
references.pmid: 23730418
references.citation: World J Gastroenterol. 2010 Mar 28;16(12):1473-81
references.pmid: 20333787
references.citation: Oncogene. 2005 Jul 21;24(31):4908-20
references.pmid: 15824730
references.citation: Cancer Res. 2006 Oct 15;66(20):9789-93
references.pmid: 17047036
references.citation: Cancer Res. 1998 Oct 1;58(19):4383-90
references.pmid: 9766668
references.citation: J Pineal Res. 2006 Jan;40(1):18-26
references.pmid: 16313494
references.citation: Nucleic Acids Res. 2011 Sep 1;39(16):6932-43
references.pmid: 21596782
references.citation: J Pineal Res. 2012 Aug;53(1):91-8
references.pmid: 22288984
references.citation: J Pineal Res. 2012 Nov;53(4):335-43
references.pmid: 22536785
references.citation: J Pineal Res. 2006 Mar;40(2):158-67
references.pmid: 16441553
references.citation: Nat Protoc. 2007;2(5):1236-47
references.pmid: 17546019
references.citation: J Biol Chem. 2009 Apr 17;284(16):10361-6
references.pmid: 19218236
references.citation: J Pineal Res. 2013 Apr;54(3):303-12
references.pmid: 23110400
references.citation: J Pineal Res. 2004 Sep;37(2):107-12
references.pmid: 15298669
references.citation: Carcinogenesis. 2005 Feb;26(2):263-70
references.pmid: 15375012
references.citation: Mol Endocrinol. 2012 Nov;26(11):1808-20
references.pmid: 23002080
references.citation: J Pineal Res. 2012 Mar;52(2):244-52
references.pmid: 22050627
references.citation: Br J Cancer. 2013 Feb 5;108(2):442-9
references.pmid: 23257900
references.citation: Pharmacol Rev. 2003 Jun;55(2):325-95
references.pmid: 12773631
references.citation: Genes Dev. 2012 Apr 15;26(8):791-6
references.pmid: 22465953
references.citation: J Pineal Res. 2009 Mar;46(2):172-80
references.pmid: 19175854
references.citation: Cancer Res. 2002 Apr 1;62(7):2141-50
references.pmid: 11929836
references.citation: Cancer Detect Prev. 2006;30(2):118-28
references.pmid: 16647824
references.citation: Mol Cell. 2010 Jul 30;39(2):247-58
references.pmid: 20670893
references.citation: Cancer Lett. 1992 Jul 10;64(3):249-56
references.pmid: 1638517
references.citation: J Pineal Res. 2008 Nov;45(4):532-40
references.pmid: 19012662
references.citation: J Biol Chem. 2012 Jul 6;287(28):23489-501
references.pmid: 22553202
references.citation: Cell Mol Life Sci. 2013 Jun;70(12):2139-57
references.pmid: 23007844
references.citation: Exp Mol Med. 2003 Aug 31;35(4):263-8
references.pmid: 14508065
references.citation: J Clin Invest. 2010 Feb;120(2):545-58
references.pmid: 20071779
references.citation: Dermatoendocrinol. 2011 Jan;3(1):27-31
references.pmid: 21519406
references.citation: Histol Histopathol. 2012 Jan;27(1):49-58
references.pmid: 22127596
references.citation: Toxicol Mech Methods. 2012 Oct;22(8):631-7
references.pmid: 22889322
references.citation: FASEB J. 2006 Feb;20(2):269-76
references.pmid: 16449799
references.citation: J Cell Mol Med. 2009 Sep;13(9B):3632-43
references.pmid: 18681908
references.citation: Expert Rev Mol Med. 2009 Feb 05;11:e5
references.pmid: 19193248
references.citation: Hum Pathol. 2011 Feb;42(2):204-13
references.pmid: 21056897
references.citation: Acta Biochim Pol. 2003;50(4):1129-46
references.pmid: 14740000
references.citation: Eur J Pharmacol. 2013 Sep 5;715(1-3):219-29
references.pmid: 23726949
references.citation: J Pineal Res. 2005 May;38(4):217-22
references.pmid: 15813897
references.citation: Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):E187-96
references.pmid: 22190494
references.citation: Cell Cycle. 2010 Mar 15;9(6):1218-9
references.pmid: 20237431
references.citation: Cancer Lett. 2013 Jun 10;333(2):180-6
references.pmid: 23352644